BLFS

NEUTRALM&A

BioLife Solutions, Inc.

2026-08-19

Price

$36.47

+4.38%

This is the 2026-08-19 snapshot — the signals and analysis for BLFS as of this single trading day.

View full BLFS research hub →

Score6.3Priority

Signals5/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 9

Volume0.7xvs 20d avg

Analysis

BioLife Solutions (BLFS) is exhibiting High-Conviction Price Discovery, driven by a definitive $1.5 billion cash-and-stock acquisition agreement with Repligen and bolstered by a sharp Q2 earnings swing to profitability. The stock's PERFECT_STACK and STEADY_CLIMB signals, alongside its +13.8% relative strength versus the SPY, reflect the market pricing in the acquisition premium and the underlying strength of the acquirer's equity. With the current RISK_ON (RATES) macro regime providing a highly supportive backdrop for risk assets and M&A activity, BLFS is trading robustly as arbitrage flows dominate ahead of the expected Q4 2026 close.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKINSIDE OUTWEAK FINISH

Key Takeaways

Actionable Thesis: BLFS is trading as an M&A arbitrage play anchored to Repligen's acquisition terms ($11.25 cash plus 0.1442 RGEN shares per BLFS share), meaning future price action will closely track the acquirer's stock.
Key Risk: The primary risk is regulatory or shareholder hurdles delaying or blocking the Q4 2026 deal closure, though recent strong Q2 earnings provide a fundamental floor.
What to Watch: Monitor Repligen's (RGEN) stock price, as it dictates the variable portion of the deal value, alongside any antitrust or shareholder voting updates.

← Back to 2026-08-19 View Full BLFS History →Yahoo Finance &nearr;